The role of kidney in glucose homeostasis – SGLT2 inhibitors, a new approach in diabetes treatment

Expert Review of Clinical Pharmacology

Volumn 6, Issue 5, 2013, Pages 519-539

  Andrianesis, Vasileios ^a   Doupis, John ^a,b  

^a Naval Hospital of Salamis   (Greece)

^b Division of Diabetes   (Greece)

Author keywords

canagliflozin; dapagliflozin; glucosuria; renal gluconeogenesis; SGLT2 inhibitors; SGLT2 Na+ D glucose co transporters

Indexed keywords

2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; CANAGLIFLOZIN; GLUCOSE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFECTS; GLUCONEOGENESIS; HOMEOSTASIS; HUMAN; KIDNEY; METABOLISM; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; GLUCONEOGENESIS; GLUCOSE; GLUCOSIDES; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME;

EID: 84899603337     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2013.827399     Document Type: Review

References (102)

1. Wright E, Hirayama B, Loo D. Active sugar transport in health and disease. J. Int. Med. 261 (1), 32–43 (2007).
2. Trakatelis A. Chapter 18: Carbohydrate ingestion- glycolysis. In: Biochemistry, Volume A, Part 2. Trakatellis A (Ed.). Kiriakidis Bros, Thessaloniki, Greece, 437–464 (2001).
3. Clutter W, Cryer P. Hypoglycemia. In: Internal Medicine. Stein J (Ed.). St Louis, MO, Mosby, 1424–1430 (1994).
4. Schoolwerth A, Smith B, Culpepper R. Renal gluconeogenesis: a review. Miner. Electrolyte Metab. 14, 361–374 (1988).
5. Wirthensohn G, Guder W. Renal substrate metabolism: a review. Physiol. Rev. 66, 469–497 (1986).
6. Guder W, Ross B. Enzyme distribution along the nephron: a review. Kidney Int. 26, 101–111 (1984).
7. Gerich JE, Meyer C, Woerle HJ, Stuvoll M. Renal gluconeogenesis:its importance in human glucose homeostasis. Diabetes Care 24, 382–391 (2001).
8. Ekberg K, Landau BR, Wajngot A et al. Contributions by kidney and liver glucose production in the postabsortive state and after 60 h of fasting. Diabetes 48, 292–298 (1999).
9. Meyer C, Dostou JM, Welle SL, Gerich JE. Role of liver, kidney and skeletal muscle in the disposition of an oral glucose load: an abstract. Diabetes 48 (Suppl. 1), A289 (1999).
10. Welle S, Lilavivathana U, Campbell R. Increased plasma norepinethrine concentrations and metabolic rates following glucose ingestion in man. Metabolism 29, 806–809 (1980).
11. Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. Am. J. Physiol. 276, E78 – E84 (1999).
12. Meyer C, Dostou J, Nedkami V, Gerich J. Effects of physiological hyperinsulinemia on systemic, renal and hepatic substrate metabolism. Am. J. Physiol. 275, F915 – F921 (1998).
13. Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsortive humans. Metabolism 47, 1227–1232 (1998).
14. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J. Uptake and release of glucose by human kidney:postabsortive rates and responses to epinethrine. J. Clin. Invest. 96, 2528–2533 (1995).
15. Lemieux G, Aranda M, Fournel P, Lemieux C. Renal enzymes during experimental diabetes mellitus in the rat: role of insulin, carbohydrate metabolism, and ketoacidosis. Cancer J. Physiol. Pharmacol. 62, 70–75 (1984).
16. Weber G, Lea M, Convery H, Stamm N. Regulation of gluconeogenesis and glycolysis: studies of mechanisms controlling enzyme activity. Adv. Enzyme Regul. 5, 257–298 (1967).
17. Mithieux G, Vidal H, Zitoun C, Bruni N, Daniele N, Minassean C. Glucose- 6- phosphatase mRNA and activity are increased to the same extent in kidney and liver of diabetic rats. Diabetes 45, 891–896 (1996).
18. Mitrakou A, Plantanisiotis D, Vlachos L et al. Increased renal glucose production in insulin dependent diabetes (IDDM):contribution to systemic glucose appearance and effect of insulin repletion (Abstract). Diabetes 45, 33A (1996).
19. Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J. Clin. Invest. 102, 619–624 (1998).
20. Exton J. Gluconeogenesis. Metabolism 21, 945–990 (1972).
21. Guyton AC, Hall JE. Chapter 27: Urine Formation by the Kidneys: II Tubular processing of the Glomerular Filtrate. In: Textbook Of Medical Physiology (11th Edition). Guyton AC, Hall JE (Eds). Elsevier Saunders, Philadelphia, Pennsylvania, 327–347 (2006).
22. Wright E, Turc E. The sodium/glucose cotransport family SLC5. Pflugers. Arch. 447, 510–518 (2004).
23. Wright E, Loo D, Hirayama, B. Biology of human sodium glucose transporters. Physiol. Rev. 91, 733–791 (2011).
24. Barfuss DW, Schafer JA. Differences in active and passive glucose transport along the proximal nephron. Am. J. Physiol. 240, F322 – F332 (1981).
25. Turner RJ, Moran A. Further studies of proximal tubular brush border membrane D-glucose transport heterogeneity. J. Membr. Biol. 70, 37–45 (1982).
26. Turner R, Moran A. Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am. J. Physiol. Renal. Fluid. Electrolyte Physiol. 242, F406 – F414 (1982).
27. Kanai Y, Lee W, You G, Brown D, Hediger M. The human kidney low affinity Na_/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J. Clin. Invest. 93, 397–404 (1994).
28. Wells R, Pajor A, Kanai Y, Turk E, Wright E, Hediger M. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am. J. Physiol. Renal. Fluid. Electrolyte Physiol. 263, F459 – F465 (1992).
29. Wright E. Renal Na_-glucose cotransporters. Am. J. Physiol. Renal. Physiol. 280, F10 – F18 (2001).
30. +/d-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell Physiol. 300. C14 – C21 (2011).
31. Vallon V, Platt KA, Cunard R et al. SGLT2 Mediates Glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 22, 104–112 (2011).
32. Gorboulev V, Schürmann A, Vallon V et al. Na+-D-glucose Cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61, 187–196 (2012).
33. Vallon V, Sharma K. Sodium-glucose transport:role in diabetes mellitus and potential clinical implications. Curr. Opin. Nephrol. Hypertens 19, 425–431 (2010).
34. Turk E, Kim O, le Coutre J et al. Molecular characterization of Vibrio parahaemolyticus vSGLT:a model for sodium-coupled sugar cotransporters. J. Biol. Chem. 275, 25711–25716 (2000).
35. Parent L, Supplisson S, Loo DDF, Wright EM. Electrogenic properties of the cloned Na_/glucose cotransporter. II. A transport model under non rapid equilibrium conditions. J. Membr. Biol. 125, 63–79 (1992).
36. Schultz SG. Ion-coupled transport of organic solutes across biological membranes. In: Physiology of Membrane Disorders. Andreoli TE, Hoffman JF, Fanestil DD (Eds). Plenum, New York, 283–294 (1985).
37. Augustin R. The protein family of glucose transport facilitators: It’s not only about glucose after all: Critical review. IUBMB Life 62 (5), 315–333 (2010).
38. Pao SS, Paulsen IT, Saier MH Jr. Major facilitator super family. Microbiol. Mol. Biol. Rev. (Washington, DC) 62, 1–34 (1998).
39. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol. Rev. 74, 993–1026 (1994).
40. Mogensen CE. Maximum tubular absorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand. J. Clin. Lab. Invest. 28, 101–109 (1971).
41. Vestri S, Okamoto MM, de Freitas HS et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J. Membr. Biol. 182, 105–112 (2001).
42. Marks J, Carvou NJ, Debnam ES, Srai SK, Unwin RJ. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J. Physiol. 553, 137–145 (2003).
43. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non–insulin-dependent diabetes. Diabetes 54, 3427–3434 (2005).
44. Santer R, Schneppenheim R, Dombrowski A, Gotze H, Steinmann B, Schaub J. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat. Genet. 17, 324–326 (1997).
45. Manz F, Bickel H, Brodehl J et al. Fanconi-Bickel syndrome. Pediatr. Nephrol. 1, 509–518 (1987).
46. Scholl-Burgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: The original patient and his natural history. Nephrol. Dial. Transplant. 19, 2394–2396 (2004).
47. Oemar BS, Byrd DJ, Brodehl J. Complete absence of tubularglucose reabsorption: A new type of renal glucosuria (type 0). Clin. Nephrol. 27, 156–160 (1987).
48. De Marchi S, Cecchin E, Basile A et al. Is renal glycosuria a benign condition? Proc. Eur. Dial. Transplant. Assoc. 20, 681–685 (1983).
49. Santer R, Calado J. Familial renal glucosuria and SGLT2: From a mendelian trait to a therapeutic target: In-depth review. Clin. J. Am. Soc. Nephrol. 5, 133–141 (2010).
50. White JR. Apple trees to sodium glucose co-transporter inhibitors: A review of SGLT2 inhibition. Clin. Diabetes 28 (1), 5–10 (2010).
51. Vick H, Diedrich DF, Baumann K. Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am. J. Physiol. 224, 552–557 (1973).
52. Lee WS, Wells RG, Hediger MA. The high affinity NA/glucose cotransporter: re-evaluation and distribution of expression. J. Biol. Chem. 269, 12032–12039 (1994)
53. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose absorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr. Pract. 14, 782–790 (2008).
54. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 62, 1279–1284 (2008).
55. Boldys A, Okopien B. Inhibitors of type 2 sodium glucose co-transporters – a new strategy for diabetes treatment: Review. Pharmacol. Rep. 61, 778–784 (2009).
56. Wilding JP, Norwood P, T’joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32, 1656–1662 (2009).
57. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375, 2223–2233 (2010).
58. Nagata T, Fukazawa M, Honda K et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am. J. Physiol. Endocrinol. Metab. 15, 304 (4), E414 – E423 (2013).
59. Yamaguchi K, Kato M, Suzuki M et al. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. J. Pharmacol. Exp. Ther. 345 (1), 52–61 (2013).
60. Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48, 1794–1800 (1999).
61. Misra M. SGLT2 inhibitors:a promising new therapeutic option for treatment of type 2 diabetes mellitus: Review. J. Pharm. Pharmacol. 65, 317–327 (2012).
62. Hussey EK, Clark RV, Amin DM et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J. Clin. Pharmacol. 50, 623–635 (2010).
63. Fujimori Y, Katsuno K, Nakashima I et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther. 327, 268–276 (2008).
64. Kapur A, O’Connor-Semmes RL, Hussey EK et al. First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus (T2DM). Diabetes 58 (Suppl. 1A), 509P (2009).
65. Dobbins RL, O'Connor-Semmes R, Kapur A et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab. 14 (1), 15–22 (2012).
66. Mudaliar S, Armstrong DA, Mavian AA et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care 35 (11), 198–200 (2012)
67. Nair S, Wilding JP. Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus: Review. J. Clin. Endocrinol. Metab. 95, 34–42 (2010).
68. Wancewicz EV, Bernd AS, Meibohm B et al. Long-term safety and efficacy of ISIS-388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. Diabetes 57 (Suppl. 1), A96 (Abstract).
69. Bhanot S, Murray SF, Booten SL et al. ISIS388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well-tolerated. Proceeding of the 69th Scientific Session of the American Diabetes Association, LA (Abstract 328-OR) (2009).
70. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium dependent glucose cotransporter2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 51, 1145–1149 (2008).
71. Han S, Hagan DL, Taylor JR. Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats. Diabetes 57, 1723–1729 (2008).
72. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise:a randomized, double- blind, placebo- controlled, phase III trial. Diabetes Care 33 (10), 2217–2224 (2010).
73. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride:a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 13 (10), 928–938 (2011).
74. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-Glucose cotransport inhibitionwith dapagliflozin in type 2 diabetes. Diabetes Care 32, 650–657 (2009).
75. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin:a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34 (9), 2015–2022 (2011).
76. Abdul-Ghani MA, Norton L, de Fronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr. Diab. Rep. 12, 230–238 (2012).
77. Liang Y, Arakawa K, Ueta K et al Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models. PLoS ONE 7 (2), e30555 (2012)
78. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr. Med. Res. Opin. 28 (7), 1173–1178 (2012).
79. Rosenstock J, Aggarwal N, Polidori D et al Dose-Ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35, 1232–1238 (2012).
80. Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes. Metab. 14, 539–545 (2012).
81. Stenlof K, Cefalu WT, Kim KA et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes. Metab. 15, 372–382 (2013).
82. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. 15 (5): 463–473 (2013).
83. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85 (5), 513–519 (2009)
84. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35, 1473–1478 (2012).
85. Centers for Disease Control and Prevention. Diabetes Successes and Opportunities for Population-Based Prevention and Control. (2011). www.cdc.gov/chronicdisease/resources/publications/AAG/ddt.htm (Last accessed 1 April 2013)
86. FDA Advisory Committee Meeting. FDA briefing document. NDA 202293. (Dapagliflozin tablets 5 mg and 10 mg. Sponsor: Bristol Myers Squibb). (2011). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf (Last accessed on 27 March 2013)
87. BHV Pharmaceuticals and Kissei Pharmaceutical Co. Ltd. Sign Exclusive Worldwide License Agreement for Late-Stage Development Product Remogliflozin Etabonate. (2011). www.prweb.com/releases/2011/01/prweb4946674.htm (Last accessed on 9 July 2013)
88. Irony I. FDA advisory committee meeting. (2011). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM264312.pdf (Last accessed on 27 March 2013).
89. Pollack A. Diabetes Drug Dapagliflozin. Rejected by FDA. The New York Times. (2011). www.nytimes.com/2011/07/20/business/diabetes-drug-dapagliflozin-rejected-by-fda-panel.html?_r=0 (Last accessed on 1 May 2013)
90. Pollack A. FDA Delays Approval of New Diabetes Drug. The New York Times. (2012). http://prescriptions.blogs.nytimes.com/2012/01/19/f-d-a-delays-approval-of-new-diabetes-drug/. (Last accessed on 10 May 2013)
91. Pierson R. EU okays Bristol-Astra diabetes drug after US rejection. Reuters. (2012). www.reuters.com/article/2012/11/14/us-bristolmyers-astrazeneca-diabetes-idUSBRE8AD1JR20121114 (Last accessed on 10 May 2013)
92. Clarke T. FDA approves Johnson & Johnson diabetes drug, canaglilozin. Reuters. (2013). www.reuters.com/article/2013/03/29/us-usa-johnsonandjohnson-diabetes-idUSBRE92S0EY20130329) (Last accessed on 10 May 2013)
93. Johnson & Johnson. Janssen Submits European marketing authorization Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes. (2013). www.investor.jnj.com/releasedetail.cfm?releaseid=746417) (Last accessed on 10 May 2013)
94. FDA Advisory Committee Meeting. FDA briefingdocument. NDA 204042. (Invokana (canagliflozin) Tablets, Applicant: Janssen Pharmaceuticals, Inc. (2013). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf (Last accessed on: 5 May 2013)
95. Janssen Research & Development, LLC. First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease. (2012). http://files.shareholder.com/downloads/JNJ/2429718328x0x603008/9ed11164-5d23-4c5b-a52ed5a3ac18b5a4/JNJ_News_2012_10_2_Financial_Releases.pdf (Last accessed on 5 May 2013)
96. Eli Lilly and Company; Boehringer Ingelheim. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment. Reuters. (2013). www.reuters.com/article/2013/03/25/boehringer-eli-lilly-idUSnPnDE82380+160+PRN20130325 (Last accessed on 10 May 2013)
97. Astellas Pharma Inc. Astellas Pharma Inc Submits Application for Marketing Approval of Ipragliflozin (ASP1941), SGLT@ inhibitor for Treatment of Type 2 Diabetes in Japan. Reuters. (2013). http://in.reuters.com/finance/stocks/4503.T/key-developments/article/2711533 (Last accessed on 10 May 2013)
98. Astellas Pharma Inc.: Submits application for Marketing Approval of Ipragliflozin (ASP1941), SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan. (2013). www.astellas.com/en/corporate/news/pdf/130313_1_Eg.pdf (Last accessed on 9 July 2013)
99. Chugai Pharmaceutical: Development Pipeline. (2013). www.chugai-pharm.co.jp/hc/ss/english/ir/reports_downloads/pipeline.html (Last accessed on 9 July 2013)
100. Lexicon Pharmaceuticals pipeline. (2013). http://lexpharma.com/pipeline/lx4211.html (Last accessed on 9 July 2013)
101. Filing for Marketing Approval of SGLT2 Inhibitor Luseogliflozin Hydrate (TS-071) in Japan. (2013). www.taisho-holdings.co.jp/en/release/2013/2013041801-e.pdf (Last accessed on: 9 July 2013)
102. Pfizer pipeline. (2013). www.pfizer.com/files/research/pipeline/2013_0509/pipeline_2013_0509.pdf (Last accessed on 9 July 2013)